Heparin-induced thrombocytopenia, a prothrombotic disease.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2007-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.HOC.2006.11.003PMID 17258119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heparin‐induced thrombocytopenia

  2009cited by this paper
• Heparin-induced thrombocytopenia (HIT)

  2006cited by this paper
• Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings

  2006cited by this paper
• Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

  2006cited by this paper
• The Cost-Effectiveness of Argatroban Treatment in Heparin-Induced Thrombocytopenia: The Effect of Early Versus Delayed Treatment

  2006cited by this paper
• Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin‐Induced Thrombocytopenia

  2006cited by this paper
• A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.

  2006cited by this paper
• Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.

  2006cited by this paper
• A prospective study of the prevalence of heparin‐induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis

  2006cited by this paper
• Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.

  2006cited by this paper
• Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization.

  2006cited by this paper
• Evaluation of Bivalirudin Treatment for Heparin‐Induced Thrombocytopenia in Critically Ill Patients with Hepatic and/or Renal Dysfunction

  2006cited by this paper
• Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia

  2006cited by this paper
• Lepirudin Anticoagulation for Heparin‐Induced Thrombocytopenia After Cardiac Surgery in a Pediatric Patient

  2006cited by this paper
• Recombinant Factor VIIa for Refractory Bleeding After Cardiac Surgery Secondary to Anticoagulation with the Direct Thrombin Inhibitor Lepirudin

  2006cited by this paper
• How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?

  2006cited by this paper
• Argatroban Anticoagulation in Pediatric Patients: A Literature Analysis

  2006cited by this paper
• Successful Recovery After an Overdose of Argatroban

  2006cited by this paper
• The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment.

  2005cited by this paper
• Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux

  2005cited by this paper
• Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.

  2005cited by this paper
• A Comparison of Lepirudin and Argatroban Outcomes

  2005cited by this paper
• Transitioning from Argatroban to Warfarin Therapy in Patients with Heparin-induced Thrombocytopenia

  2005cited by this paper
• Lepirudin in patients with heparin‐induced thrombocytopenia – results of the third prospective study (HAT‐3) and a combined analysis of HAT‐1, HAT‐2, and HAT‐3

  2005cited by this paper
• New approaches to the diagnosis of heparin-induced thrombocytopenia.

  2005cited by this paper
• Finding haystacks full of needles: from Opus to Osler.

  2005cited by this paper
• The heparin-induced thrombocytopenia task force model: implementing quality improvement and economic outcome initiatives.

  2005cited by this paper
• Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

  2005cited by this paper
• Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

  2005cited by this paper
• Delayed-onset heparin-induced thrombocytopenia.

  2005cited by this paper
• Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

  2005cited by this paper
• Role of platelet factor 4–heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis

  2005cited by this paper
• Early‐Onset Heparin‐Induced Thrombocytopenia After a 165‐Day Heparin‐Free Interval: Case Report and Review of the Literature

  2005cited by this paper
• Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

  2005cited by this paper
• Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery.

  2005cited by this paper
• Heparin-induced Thrombocytopenia Type II in Subarachnoid Hemorrhage Patients: Incidence and Complications

  2005cited by this paper
• The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy.

  2005cited by this paper
• Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study.

  2005cited by this paper
• Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.

  2005cited by this paper
• Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban

  2005cited by this paper
• Thrombocytopenia following heparin flush.

  2005cited by this paper
• Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.

  2005cited by this paper
• Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis

  2005cited by this paper
• Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.

  2005cited by this paper
• Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning from Argatroban to Warfarin

  2005cited by this paper
• Treatment of heparin-induced thrombocytopenia: a critical review.

  2004cited by this paper
• Risk of thrombosis in patients with malignancy and heparin‐induced thrombocytopenia

  2004cited by this paper
• Treatment of heparin-induced thrombocytopenia with fondaparinux.

  2004cited by this paper
• Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin

  2004cited by this paper
• Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia.

  2004cited by this paper
• Antibodies to Platelet Factor 4/Heparin are Associated with Elevated Endothelial Cell Activation Markers in Patients with Acute Coronary Ischemic Syndromes

  2004cited by this paper
• Frequency of Heparin-Platelet Factor 4 Antibodies among Patients with Acute Coronary Syndromes Presenting to the Emergency Department.

  2004cited by this paper
• Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

  2004cited by this paper
• A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.

  2004cited by this paper
• Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.

  2004cited by this paper
• Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.

  2004cited by this paper
• Argatroban Dosage in Critically Ill Patients with HIT.

  2004cited by this paper
• Argatroban Anticoagulation in Conjunction with Glycoprotein IIb/IIIa Inhibition in Patients Undergoing Percutaneous Coronary Intervention: An Open-Label, Nonrandomized Pilot Study

  2004cited by this paper
• Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality.

  2004cited by this paper
• Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient).

  2004cited by this paper
• Heparin-induced thrombocytopenia in the emergency department.

  2004cited by this paper
• Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia

  2004cited by this paper
• Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes

  2004cited by this paper
• Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients.

  2004cited by this paper
• Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.

  2004cited by this paper
• Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.

  2004cited by this paper
• Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin.

  2004cited by this paper
• Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy

  2004cited by this paper
• Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia

  2003cited by this paper
• Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia.

  2003cited by this paper
• How I treat heparin-induced thrombocytopenia and thrombosis.

  2003cited by this paper
• Heparin-induced thrombocytopenia: twenty-nine years later.

  2003cited by this paper
• Subacute stent thrombosis associated with a heparin‐coated stent and heparin‐induced thrombocytopenia

  2003cited by this paper
• The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study.

  2003cited by this paper
• Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia

  2003cited by this paper
• Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

  2003cited by this paper
• Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin.

  2003cited by this paper
• Anti-heparin-platelet factor 4 antibody is a risk factor for vascular access obstruction in patients undergoing hemodialysis.

  2003cited by this paper
• Lepirudin for the Treatment of Heparin-Induced Thrombocytopenia

  2003cited by this paper
• Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.

  2003cited by this paper
• The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.

  2003cited by this paper
• Danaparoid for heparin‐induced thrombocytopenia: an analysis of treatment failures

  2003cited by this paper
• Treatment of Heparin-Induced Thrombocytopenia: An Overview

  2003cited by this paper
• Heparin-induced thrombocytopenia and cardiac surgery.

  2003cited by this paper
• Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.

  2003cited by this paper
• Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems

  2003cited by this paper
• Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia.

  2003cited by this paper
• Anti-Platelet Factor 4/Heparin Antibodies: An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes

  2003cited by this paper
• Frequency of Heparin‐Induced Thrombocytopenia in Critical Care Patients

  2003cited by this paper
• Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.

  2003cited by this paper
• Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia

  2003cited by this paper
• Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia

  2003cited by this paper
• Heparin‐induced thrombocytopenia: pathogenesis and management

  2003cited by this paper
• Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia.

  2003cited by this paper
• Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia

  2002cited by this paper
• Heparin-induced thrombocytopenia: a common complication in cardiac transplant recipients.

  2002cited by this paper
• Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia.

  2002cited by this paper
• Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers

  2002cited by this paper
• Hirudin In Renal Insufficiency

  2002cited by this paper

• Near-infrared vascular image segmentation using improved level set method

  2023cites this paper
• Thrombotic disorders and laboratory assessment

  2020cites this paper
• Molecular basis of hemostatic and thrombotic diseases

  2020cites this paper
• Protamine, is something fishy about it? The spectre of anaphylaxis continues.

  2019cites this paper
• Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

  2018influential citation
• Heparin-Induced Thrombocytopenia and Thrombosis: Preventing your Thrombolysis Practice from Taking a HITT

  2017cites this paper
• [Heparin-induced thrombocytopenia type II (HIT II) : A medical-economic view].

  2017cites this paper
• Pulmonary Embolism due to Heparin-Induced Thrombocytopenia (HIT): A Case Report of an 11-year-old Child Undergoing Scoliosis Surgery and Literature Review

  2017influential citation
• Bivalirudin in off-pump coronary artery bypass graft in a patient with heparin-induced thrombocytopenia: a case report of its use.

  2015cites this paper
• Anticoagulation strategies in heparin‐induced thrombocytopenia associated with renal replacement therapy

  2014cites this paper
• A man with acute venous thromboembolism and thrombocytopenia

  2014cites this paper
• Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.

  2014cites this paper
• Chapter 7 – Vascular System and Hematology

  2014cites this paper
• Anaphylaxis, Allergy, and Adverse Drug Reactions: Important Considerations for Perioperative Management

  2013cites this paper
• Trombocitopenia inducida por heparina

  2012cites this paper
• Heparin-Induced Thrombocytopenia: An Update

  2012cites this paper
• A Rare Case of Acute Myocardial Infarction due to Coronary Artery Dissection and Heparin-Induced Thrombocytopenia

  2012influential citation
• Glycosaminoglycans in Atherosclerosis and Thrombosis

  2011cites this paper
• Trombocitopenia inducida por heparina de bajo peso molecular

  2011cites this paper
• Guidelines for the prevention of intravascular catheter-related infections.

  2011cites this paper
• Donor heparinization is not a contraindication to liver transplantation even in recipients with acute heparin‐induced thrombocytopenia type II: a case report and review of the literature

  2011cites this paper
• Heparin-induced thrombocytopenia

  2011cites this paper
• Deep Venous Thrombosis and Pulmonary Embolism

  2011cites this paper
• Kατευθυντήριες Oδηγίες για την Πρόληψη Λοιμώξεων σχετιζόμενων με Eνδαγγειακούς Kαθετήρες

  2011cites this paper
• Molecular Basis of Disorders of Hemostasis and Thrombosis

  2010cites this paper
• An Overview of Heparin-Induced Thrombocytopenia

  2010cites this paper
• Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.

  2010cites this paper
• Red Blood Cell and Bleeding Disorders

  2010cites this paper
• A fatal case of heparin-induced thrombocytopenia and thrombosis.

  2010cites this paper
• Heparin–platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study

  2010influential citation
• Drugs that affect blood coagulation, fibrinolysis, and hemostasis

  2010cites this paper
• Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis, and Review of Pharmacotherapy

  2009cites this paper
• Chapter 15 – Molecular Basis of Hemostatic and Thrombotic Diseases

  2009cites this paper
• Cardiac Surgery Essentials for Critical Care Nursing

  2009cites this paper
• Heparin-Induced Thrombocytopenia With Thrombosis After Endovascular Aneurysm Repair

  2009cites this paper
• Heparin‐Induced Thrombocytopenia: Your Questions Answered

  2009cites this paper
• Thrombocytopenia and other hot topics.

  2009influential citation
• Clinical Experience of Argatroban in Germany

  2008cites this paper
• Thrombocytopenia after total knee arthroplasty.

  2008cites this paper
• Heparin-induced thrombocytopenia: overview and treatment.

  2008cites this paper
• Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results

  2008cites this paper
• Malignancy and Thrombosis

  2008cites this paper
• Heparin-Induced Thrombocytopenia Table 3 Factors Complicating the Diagnosis of Heparin-Induced Thrombocytopenia ( HIT ) : Differential Diagnosis

  2008cites this paper
• Heparin-Induced Thrombocytopenia

  2008cites this paper
• The anticoagulated patient: strategies for effective blood loss management.

  2007cites this paper
• Heparin‐Induced Thrombocytopenia

  2007cites this paper
• Heparin-induced thrombocytopenia: a review.

  2006cites this paper
• Guidelines for the prevention of intravascular catheter-related infections.

  2002cites this paper
• Anaphylactic and Anaphylactoid Reactions in the Surgical Patient

  year unknowncites this paper